156 related articles for article (PubMed ID: 8580020)
1. Calcitriol oral pulse therapy in children with renal osteodystrophy.
Cano F; Delucchi A; Wolff E; Rodriguez E; Fuentes A
Pediatr Nephrol; 1995 Oct; 9(5):606-8. PubMed ID: 8580020
[TBL] [Abstract][Full Text] [Related]
2. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients.
Gadallah MF; Arora N; Torres C; Ramdeen G; Schaeffer-Pautz A; Moles K
Adv Perit Dial; 2000; 16():303-7. PubMed ID: 11045316
[TBL] [Abstract][Full Text] [Related]
3. Marked improvement in parameters of renal osteodystrophy with the use of intraperitoneal calcitriol.
Arora N; Sandroni S; Moles K
Adv Perit Dial; 1992; 8():62-4. PubMed ID: 1361854
[TBL] [Abstract][Full Text] [Related]
4. Renal osteodystrophy in children with end-stage kidney failure.
Chan JC
Va Med; 1979 May; 106(5):384-90. PubMed ID: 463255
[TBL] [Abstract][Full Text] [Related]
5. Parenteral calcitriol for treatment of severe renal osteodystrophy in children with chronic renal insufficiency.
Trachtman H; Gauthier B
J Pediatr; 1987 Jun; 110(6):966-70. PubMed ID: 3585613
[TBL] [Abstract][Full Text] [Related]
6. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB
Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
[TBL] [Abstract][Full Text] [Related]
7. 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration alone.
Coen G; Taccone Gallucci M; Bonucci E; Ballanti P; Bianchi AR; Bianchini G; Matteucci MC; Mazzaferro S; Picca S; Taggi F; Cinotti GA; Casciani CU
Miner Electrolyte Metab; 1983; 9(1):19-27. PubMed ID: 6687749
[No Abstract] [Full Text] [Related]
8. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.
Andress DL; Norris KC; Coburn JW; Slatopolsky EA; Sherrard DJ
N Engl J Med; 1989 Aug; 321(5):274-9. PubMed ID: 2631697
[TBL] [Abstract][Full Text] [Related]
9. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy.
Goodman WG; Ramirez JA; Belin TR; Chon Y; Gales B; Segre GV; Salusky IB
Kidney Int; 1994 Oct; 46(4):1160-6. PubMed ID: 7861712
[TBL] [Abstract][Full Text] [Related]
10. [Prevention and treatment of renal osteodystrophy: present and future].
Fernández E; Craver L
Nefrologia; 2006; 26 Suppl 3():19-27. PubMed ID: 17469423
[No Abstract] [Full Text] [Related]
11. Serum markers of low-turnover bone disease in Mexican children with chronic kidney disease undergoing dialysis.
Avila-Díaz M; Matos M; García-López E; Prado MD; Castro-Vázquez F; Ventura MD; González E; Amato D; Paniagua R
Perit Dial Int; 2006; 26(1):78-84. PubMed ID: 16538879
[TBL] [Abstract][Full Text] [Related]
12. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.
Muirhead N; Adami S; Fraser RA; Catto GR; Edward N; O'Riordan JL
Proc Eur Dial Transplant Assoc; 1981; 18():567-72. PubMed ID: 6895786
[No Abstract] [Full Text] [Related]
13. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
Massry SG; Goldstein DA; Malluche HH
Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
[No Abstract] [Full Text] [Related]
14. Pulse dose oral calcitriol therapy for renal osteodystrophy: literature review and practice recommendations.
Dahl NV; Foote EF
ANNA J; 1997 Oct; 24(5):550-5. PubMed ID: 9392738
[TBL] [Abstract][Full Text] [Related]
15. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
Quarles LD; Yohay DA; Carroll BA; Spritzer CE; Minda SA; Bartholomay D; Lobaugh BA
Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
[TBL] [Abstract][Full Text] [Related]
16. Are new vitamin D analogues in renal bone disease superior to calcitriol?
Salusky IB
Pediatr Nephrol; 2005 Mar; 20(3):393-8. PubMed ID: 15690188
[TBL] [Abstract][Full Text] [Related]
17. Intravenous versus oral calcitriol therapy in renal osteodystrophy: results of a prospective, pulsed and dose-comparable study.
Mazzaferro S; Pasquali M; Ballanti P; Bonucci E; Di Sanza P; Sardella D; Taggi F; Coen G
Miner Electrolyte Metab; 1994; 20(3):122-9. PubMed ID: 7816000
[TBL] [Abstract][Full Text] [Related]
18. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up.
Spasovski GB; Sikole A; Gelev S; Masin-Spasovska J; Freemont T; Webster I; Gill M; Jones C; De Broe ME; D'Haese PC
Nephrol Dial Transplant; 2006 Aug; 21(8):2217-24. PubMed ID: 16595583
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal calcitriol in infants on peritoneal dialysis.
Cano FJ; Azocar MA; Guerrero JL; Delucchi MA; Lillo AM; Emilfork M; Rodríguez EE
Perit Dial Int; 2007; 27(6):681-6. PubMed ID: 17984431
[TBL] [Abstract][Full Text] [Related]
20. Osteodystrophy of dialysed patients treated with vitamin D.
Verberckmoes R; Bouillon R; Krempien B
Proc Eur Dial Transplant Assoc; 1973; 10(0):217-26. PubMed ID: 4370246
[No Abstract] [Full Text] [Related]
[Next] [New Search]
